# Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)

> **NCT03974022** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Dizal Pharmaceuticals** · enrollment: 315 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Sunvozertinib

## Key facts

- **NCT ID:** NCT03974022
- **Lead sponsor:** Dizal Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-07-09
- **Primary completion:** 2024-07-29
- **Final completion:** 2026-12
- **Target enrollment:** 315 (ACTUAL)
- **Last updated:** 2026-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03974022

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03974022, "Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03974022. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*